Harkarandeep Singh

ORCID: 0009-0007-5711-7348
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sepsis Diagnosis and Treatment
  • COVID-19 Clinical Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Intensive Care Unit Cognitive Disorders
  • Respiratory Support and Mechanisms
  • COVID-19 and healthcare impacts
  • Immunotherapy and Immune Responses
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Acute Kidney Injury Research
  • Mechanical Circulatory Support Devices
  • Cardiac Structural Anomalies and Repair
  • vaccines and immunoinformatics approaches
  • Iron Metabolism and Disorders
  • Multiple Myeloma Research and Treatments
  • Disaster Response and Management
  • Renal cell carcinoma treatment
  • Long-Term Effects of COVID-19
  • Neurological Complications and Syndromes
  • Colorectal Cancer Screening and Detection
  • Venous Thromboembolism Diagnosis and Management
  • 3D Printing in Biomedical Research
  • Infectious Encephalopathies and Encephalitis
  • Muscle and Compartmental Disorders
  • FinTech, Crowdfunding, Digital Finance
  • Heart Failure Treatment and Management

Rochester General Hospital
2023-2024

Indian Institute of Toxicology Research
2024

Brigham and Women's Hospital
2021

King Edward Memorial Hospital and Seth G.S. Medical College
2017

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 ICPi-AKI and control who received ICPis contemporaneously but did not develop from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of its recovery. A multivariable Cox model estimate the effect ICPi rechallenge versus no survival following ICPi-AKI. Results occurred at a...

10.1136/jitc-2021-003467 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2021-10-01

OBJECTIVES: Hypercoagulability may be a key mechanism for acute organ injury and death in patients with severe coronavirus disease 2019, but the relationship between elevated plasma levels of d -dimer, biomarker coagulation activation, mortality has not been rigorously studied. We examined independent association -dimer critically ill 2019. DESIGN: Multicenter cohort study. SETTING: ICUs at 68 hospitals across United States. PATIENTS: Critically adults 2019 admitted to March 4, 2020, May 25,...

10.1097/ccm.0000000000004917 article EN Critical Care Medicine 2021-02-12

4529 Background: IMA901 is a therapeutic cancer vaccine based on the selection of naturally presented tumor-associated peptides (9 HLA-class I- and 1 HLA class II-binding peptides). A previous phase I study showed significant correlation disease control rate (DCR) at 3 mo with T-cell responses to multiple but no vaccinated peptide. Methods: HLA-A*02+ patients clear-cell RCC documented progression during or after first-line cytokine- TKI-based therapy were randomized 1:1 receive up 17...

10.1200/jco.2010.28.15_suppl.4529 article EN Journal of Clinical Oncology 2010-05-20
Shruti Gupta Ian A. Strohbehn Qiyu Wang Paul Hanna Rituvanthikaa Seethapathy and 95 more Jason Prosek Sandra M. Herrmann Ala Abudayyeh A. Bilal Malik Sebastian Loew Christopher A. Carlos Wei‐Ting Chang Pazit Beckerman Zain Mithani Chintan V. Shah Amanda D. Renaghan Sophie de Seigneux Luca Campedel Abhijat Kitchlu Daniel Sanghoon Shin Gaia Coppock Nuttha Lumlertgul Pablo García David I. Ortiz-Melo Arash Rashidi Ben Sprangers Vikram Aggarwal Karolina Benesova Kenar D. Jhaveri Frank B. Cortazar Astrid Weins Yiqin Zuo Meghan J. Mooradian Kerry L. Reynolds David E. Leaf Meghan E. Sise Luca Campedel Joe‐Elie Salem Corinne Isnard Bagnis Shruti Gupta David E. Leaf Harkarandeep Singh Shveta S. Motwani Naoka Murakami Maria Clarissa Tio Suraj Sarvode Mothi Umut Selamet Astrid Weins Sebastian Loew Kai M. Schmidt‐Ott Wei‐Ting Chang Kenar D. Jhaveri Rimda Wanchoo Yuriy Khanin Jamie S. Hirsch Vipulbhai Sakhiya Daniel Stalbow Sylvia Wu David I. Ortiz-Melo Marlies Ostermann Nuttha Lumlertgul Nina Seylanova Armando Cennamo Anne Rigg Nisha Shaunak Zoé A. Kibbelaar Karolina Benesova Priya Deshpande Meghan E. Sise Kerry L. Reynolds Harish Seethapathy Meghan Lee Ian A. Strohbhen Meghan J. Mooradian Paul Hanna Qiyu Wang Rituvanthikaa Seethapathy Sandra M. Herrmann Busra Isik Ilya Glezerman Frank B. Cortazar Vikram Aggarwal Sunandana Chandra Jason Prosek Sethu M. Madhavan Dwight H. Owen Marium Husain Pazit Beckerman Sharon Mini Shuchi Anand Pablo García Aydin Kaghazchi Sunil Rangarajan Daniel Sanghoon Shin Grace Cherry Christopher A. Carlos Raymond K. Hsu Andrey Kisel Arash Rashidi Sheru Kansal

10.1016/j.kint.2022.07.019 article EN Kidney International 2022-08-11

2587 Background: IMA901 is a therapeutic cancer vaccine based on the selection of naturally presented tumor-associated peptides (9 HLA class I- and 1 II-binding peptides). A previous phase I study showed significant correlation disease control rates (DCR) at 3 months with T-cell responses to multiple but not vaccinated peptide. Methods: 68 HLA-A*02-positive metastatic clear-cell RCC patients progressing during or after first-line cytokine TKI therapy were randomized 1:1 receive repeated...

10.1200/jco.2010.28.15_suppl.2587 article EN Journal of Clinical Oncology 2010-05-20

e23325 Background: Proteasome inhibitors (PI) are a class of drugs used in the treatment Multiple Myeloma. The FDA has approved three PIs for this indication (Bortezomib, Carfilzomib, and Ixazomib). Various studies, case reports have described occurrence chalazion with Bortezomib use subsequent discontinuation therapy but it’s association other from remains poorly understood. Methods: We conducted retrospective pharmacovigilance study using Adverse Event Reporting System database to analyze...

10.1200/jco.2024.42.16_suppl.e23325 article EN Journal of Clinical Oncology 2024-06-01

e19531 Background: Multiple myeloma (MM) exhibits a disproportionately higher prevalence among African American individuals. Various factors contribute to the disease's progression, severity, and prognosis. This analysis presents real-world data from National Cancer Database (NCDB) 2010 2020. Methods: Cohort of 241,446 MM patients between 2020 were analyzed. Demographic variations, including age, gender, insurance status, educational attainment, median household income, examined....

10.1200/jco.2024.42.16_suppl.e19531 article EN Journal of Clinical Oncology 2024-06-01

e19515 Background: Proteasome inhibitors (PI) are a class of drugs that used in the treatment Multiple Myeloma. There currently three PIs (Bortezomib, Carfilzomib, and Ixazomib) approved by FDA for this indication. Peripheral neuropathy has been described as one their most common side effects but association with another life-threatening neurological disorder, Posterior Reversible Encephalopathy Syndrome (PRES), remains poorly understood. Methods: We conducted retrospective pharmacovigilance...

10.1200/jco.2024.42.16_suppl.e19515 article EN Journal of Clinical Oncology 2024-06-01

Colorectal cancer is the third most common malignancy in USA and accounts for more than 1 million deaths worldwide with screening shown to reduce CRC mortality. This meta-analysis analyzed use of stool DNA average risk, asymptomatic subjects colorectal advanced precancerous lesions compared sDNA FOBT tests (gFOBT FIT). Eight studies were included from four different countries a total 39 665 subjects. Pooled sensitivity specificity detecting was 83.3% (95% CI: 60.8–94.2) 92.4% 90.1–94.1),...

10.1097/cej.0000000000000937 article EN European Journal of Cancer Prevention 2024-11-15

Introduction: Hereditary Hemochromatosis (HH), characterized by an elevated serum iron level, is linked with a significant risk of liver cirrhosis. This disease progression associated decreased quality life and survival rate, creating urgent need for research in this field. However, national-level studies investigating the factors inpatient outcomes cirrhosis HH patients are scarce. Our study aims to fill gap examining prevalence, predictors, hospital-associated population. Methods: We used...

10.14309/01.ajg.0000955620.86271.cc article EN The American Journal of Gastroenterology 2023-10-01

Introduction: Managing esophageal variceal bleeding, a life-threatening complication of liver cirrhosis, often involves the use Blakemore tube. This intervention has proven effective, but it's not without serious risks, like rupture. Though rare, this can significantly affect patient's prognosis. case report delves into an instance where patient with severe bleeding experienced rupture post tube insertion. Case Description/Methods: Our patient, 41-year-old man long history alcohol abuse that...

10.14309/01.ajg.0000960708.44485.68 article EN The American Journal of Gastroenterology 2023-10-01

Introduction: The simultaneous occurrence of gastric antral vascular ectasia (GAVE) and cecal arteriovenous malformations (AVMs), both distinct disorders known for causing gastrointestinal bleeding resultant anemia, is an unusual clinical presentation. This report brings forward intriguing case 85-year-old man grappling with recurrent anemia resulting from this unique combination disorders. Case Description/Methods: Our patient, a significant past medical history, including lymphoma, aortic...

10.14309/01.ajg.0000961948.30699.f9 article EN The American Journal of Gastroenterology 2023-10-01

Introduction: Interstitial lung disease (ILD) can appear as a rare extraintestinal inflammation in patients with inflammatory bowel (IBD) or an adverse effect of treatment. The association between these two conditions and its impact on IBD patients' morbidity mortality is not well-documented existing literature. Understanding this relationship critical it may influence treatment plans patient quality life. We aimed to conduct national-level retrospective analysis evaluate inpatient outcomes...

10.14309/01.ajg.0000953812.74016.ec article EN The American Journal of Gastroenterology 2023-10-01

Rheumatic heart disease, particularly rheumatic mitral stenosis and hemoglobinopathies, especially HbS can pose a problem in pregnancy. Though both these conditions have high incidence considerable geographic overlap India, very few studies reported diseases occurring concurrently. This is report of concurrent recently diagnosed undiagnosed sickling hemoglobinopathy post-partum woman.

10.1016/j.ihjccr.2017.10.002 article EN cc-by-nc-nd IHJ Cardiovascular Case Reports (CVCR) 2017-10-01
Coming Soon ...